Insider Buying: Enovis (NYSE:ENOV) Insider Purchases $100,024.40 in Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert acquired 5,140 shares of Enovis stock in a transaction dated Thursday, September 3rd. The shares were bought at an average price of $19.46 per share, for a total transaction of $100,024.40. Following the transaction, the insider owned 61,238 shares of the company’s stock, valued at approximately $1,191,691.48. The trade was a 9.16% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Oliver Engert also recently made the following trade(s):

• On Wednesday, September 2nd, Oliver Engert bought 2,458 shares of Enovis stock. The shares were bought at an average price of $20.32 per share, with a total value of $49,946.56.
• On Monday, June 15th, Oliver Engert bought 1,000 shares of Enovis stock. The shares were bought at an average cost of $20.92 per share, with a total value of $20,920.00.
• On Thursday, June 11th, Oliver Engert purchased 1,200 shares of Enovis stock. The stock was bought at an average price of $21.62 per share, for a total transaction of $25,944.00.
• On Wednesday, June 10th, Oliver Engert purchased 1,000 shares of Enovis stock. The stock was bought at an average price of $23.00 per share, for a total transaction of $23,000.00.

Enovis Stock Up 0.1%

ENOV opened at $18.58 on Monday. The company has a market capitalization of $1.07 billion, a PE ratio of -0.96 and a beta of 1.31. The firm has a 50-day simple moving average of $25.50 and a two-hundred day simple moving average of $24.22. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. Enovis Corporation has a 52 week low of $18.52 and a 52 week high of $34.28.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The firm had revenue of $582.78 million for the quarter, compared to analysts’ expectations of $581.84 million. During the same period in the previous year, the firm posted $0.79 earnings per share. The business’s revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on ENOV. Citizens Jmp cut their target price on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a report on Wednesday, September 2nd. BTIG Research decreased their price target on shares of Enovis from $40.00 to $36.00 and set a “buy” rating on the stock in a research note on Tuesday, September 1st. Evercore set a $32.00 price objective on shares of Enovis in a research note on Monday, July 6th. Canaccord Genuity Group reduced their target price on shares of Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, August 17th. Finally, Zacks Research upgraded shares of Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Enovis presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.38.

Trending Headlines about Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: CEO Damien McDonald bought 13,035 shares for approximately $249,620, increasing his stake by 5.57%. A substantial open-market purchase by the chief executive may signal confidence that the recent selloff has pushed the stock below its perceived value. SEC filing on CEO purchase
• Positive Sentiment: Insider Oliver Engert purchased 5,140 shares worth approximately $100,024, raising his ownership by 9.16%. The additional insider buying provides another potential confidence signal for investors. SEC filing on insider purchase
• Positive Sentiment: Zacks upgraded Enovis to Rank #2, or “Buy,” citing improving earnings prospects. Analysts’ upward earnings revisions and technically oversold conditions also suggest the possibility of a near-term trend reversal. Zacks Buy rating article
• Positive Sentiment: Canaccord Genuity maintained a Buy rating on ENOV, reinforcing the view that the selloff may have created an attractive entry point. Canaccord Genuity rating article
• Neutral Sentiment: A Q2 comparison with other specialty medical-device companies provides industry context, but the item does not identify a new material change to Enovis’ outlook. Q2 earnings comparison
• Negative Sentiment: Wells Fargo lowered its ENOV price target to $33, while Citizens JMP reduced its target to $47. Although both targets remain above the current trading range, the cuts indicate more cautious valuation assumptions and may weigh on sentiment. Wells Fargo price-target article Citizens JMP price-target article

Institutional Trading of Enovis

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP lifted its position in Enovis by 1.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock worth $90,156,000 after buying an additional 51,201 shares during the last quarter. Rubric Capital Management LP bought a new position in Enovis during the third quarter valued at $83,435,000. Paradigm Capital Management Inc. NY raised its stake in shares of Enovis by 70.2% in the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock valued at $40,420,000 after acquiring an additional 732,917 shares during the period. River Road Asset Management LLC raised its stake in shares of Enovis by 3.2% in the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after acquiring an additional 46,289 shares during the period. Finally, Private Management Group Inc. lifted its holdings in shares of Enovis by 38.8% in the 2nd quarter. Private Management Group Inc. now owns 1,365,082 shares of the company’s stock worth $28,257,000 after acquiring an additional 381,705 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.